These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 3336000)

  • 1. Pharmacodynamic model of tolerance: application to nicotine.
    Porchet HC; Benowitz NL; Sheiner LB
    J Pharmacol Exp Ther; 1988 Jan; 244(1):231-6. PubMed ID: 3336000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamic model for acute tolerance development to the electroencephalographic effects of alfentanil in the rat.
    Mandema JW; Wada DR
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1185-94. PubMed ID: 8531080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamics of acute tolerance to multiple nicotinic effects in humans.
    Fattinger K; Verotta D; Benowitz NL
    J Pharmacol Exp Ther; 1997 Jun; 281(3):1238-46. PubMed ID: 9190859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic and acute tolerance to subjective, behavioral and cardiovascular effects of nicotine in humans.
    Perkins KA; Grobe JE; Fonte C; Goettler J; Caggiula AR; Reynolds WA; Stiller RL; Scierka A; Jacob RG
    J Pharmacol Exp Ther; 1994 Aug; 270(2):628-38. PubMed ID: 8071855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abuse liability and pharmacodynamic characteristics of intravenous and inhaled nicotine.
    Henningfield JE; Miyasato K; Jasinski DR
    J Pharmacol Exp Ther; 1985 Jul; 234(1):1-12. PubMed ID: 4009494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic-pharmacodynamic modeling of tolerance to the prolactin-secreting effect of chlorprothixene after different modes of drug administration.
    Bagli M; Süverkrüp R; Quadflieg R; Höflich G; Kasper S; Möller HJ; Langer M; Barlage U; Rao ML
    J Pharmacol Exp Ther; 1999 Nov; 291(2):547-54. PubMed ID: 10525070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic and pharmacokinetic properties of an angiotensin II receptor antagonist--characterization by use of Schild regression technique in man.
    Breithaupt-Grögler K; Malerczyk C; Belz GG; Butzer R; Herrmann V; Stass H; Wensing G
    Int J Clin Pharmacol Ther; 1997 Oct; 35(10):434-41. PubMed ID: 9352392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic and pharmacodynamic modeling of mizolastine in healthy volunteers with an indirect response model.
    Deschamps C; Dubruc C; Mentre F; Rosenzweig P
    Clin Pharmacol Ther; 2000 Dec; 68(6):647-57. PubMed ID: 11180025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization and modulation of acute tolerance to nicotine in mice.
    Damaj MI; Welch SP; Martin BR
    J Pharmacol Exp Ther; 1996 Apr; 277(1):454-61. PubMed ID: 8613954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamic modeling of furosemide tolerance after multiple intravenous administration.
    Wakelkamp M; Alván G; Gabrielsson J; Paintaud G
    Clin Pharmacol Ther; 1996 Jul; 60(1):75-88. PubMed ID: 8689815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling.
    Meibohm B; Derendorf H
    Int J Clin Pharmacol Ther; 1997 Oct; 35(10):401-13. PubMed ID: 9352388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacodynamic effects of nicotine nasal spray devices on cardiovascular and pulmonary function.
    Fishbein L; O'Brien P; Hutson A; Theriaque D; Stacpoole PW; Flotte T
    J Investig Med; 2000 Nov; 48(6):435-40. PubMed ID: 11094866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PK/PD modelling of high-dose diltiazem--absorption-rate dependency of the hysteresis loop.
    Luckow V; Della Paschoa O
    Int J Clin Pharmacol Ther; 1997 Oct; 35(10):418-25. PubMed ID: 9352390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic-pharmacodynamic relationship of the cardiovascular effects of adenosine A1 receptor agonist N6-cyclopentyladenosine in the rat.
    Mathôt RA; van Schaick EA; Langemeijer MW; Soudijn W; Breimer DD; Ijzerman AP; Danhof M
    J Pharmacol Exp Ther; 1994 Feb; 268(2):616-24. PubMed ID: 8113972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of specific tolerance to nicotine infusions in dogs on chronic nicotine treatment.
    Holtz J; Sommer O; Bassenge E
    Klin Wochenschr; 1984; 62 Suppl 2():51-7. PubMed ID: 6482327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling of tolerance development and rebound effect during different intravenous administrations of morphine to rats.
    Ekblom M; Hammarlund-Udenaes M; Paalzow L
    J Pharmacol Exp Ther; 1993 Jul; 266(1):244-52. PubMed ID: 8331561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repeated administration of nicotine attenuates the development of morphine tolerance and dependence in mice.
    Haghparast A; Khani A; Naderi N; Alizadeh AM; Motamedi F
    Pharmacol Biochem Behav; 2008 Feb; 88(4):385-92. PubMed ID: 17915302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantification of effect delay and acute tolerance development to morphine in the rat.
    Gårdmark M; Ekblom M; Bouw R; Hammarlund-Udenaes M
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1061-7. PubMed ID: 8263765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of the development of tolerance to ethanol and cross-tolerance to nicotine after chronic ethanol treatment in long- and short-sleep mice.
    de Fiebre CM; Collins AC
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1398-406. PubMed ID: 8371145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-lasting rebound cue effects following single doses of nicotine and amphetamine: implications for understanding tolerance.
    Barrett RJ; Caul WF; Stadler JR; Smith RL
    Psychopharmacology (Berl); 2001 Oct; 157(4):349-57. PubMed ID: 11605093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.